Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of safety and immunogenicity of mRNA vs inactivated + mRNA COVID-19 vaccines in children 5–11 years
TCTR20220212001Phase 4Completed
- Sponsor
- Chulalongkorn University
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of mRNA COVID-19 vaccine, turkovac in coronavirus disease 2019 (COVID-19), sponsored by Chulalongkorn University. Started Mar 2022; status: completed.
02
Drugs
mRNA COVID-19 vaccineturkovac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220212001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220212001.